Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + irinotecan liposome (II)
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy consists of adebrelimab, a fully humanized IgG4 monoclonal antibody targeting programmed cell death-ligand 1 (PD-L1), and a liposomal formulation of irinotecan (Irinotecan Liposome (II)). Adebrelimab acts as an immune checkpoint inhibitor by blocking the interaction between PD-L1 and its receptors, thereby restoring and enhancing the anti-tumor immune response. Irinotecan is a cytotoxic chemotherapy agent that inhibits DNA topoisomerase I, leading to double-strand DNA breaks and the inhibition of cell replication. The liposomal delivery system is designed to prolong circulation time and improve drug accumulation within tumor tissues. This specific combination is being investigated for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in patients who have previously progressed on immune checkpoint inhibitors, sometimes in further combination with the tyrosine kinase inhibitor famitinib.
- Brand names
- Adely
- Other names
- adebrelimab + irinotecan liposome (II)SHR-1316 + Irinotecan Liposome (II)
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on adebrelimab + irinotecan liposome (II).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + irinotecan liposome (II).